Acadia Pharmaceuticals (ACAD)

Company Profile

Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who need them most. It developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Its late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research it is exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.

Company profile

Ticker

ACAD

Exchange

NASDAQ

Website

www.acadia-pharm.com

CEO

Stephen Davis

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Teva- Pharmaceutical Industries • Abbott Laboratories • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies ...

SEC CIK

0001070494

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

ACADIA Pharmaceuticals A/S • ACADIA Pharmaceuticals GmbH • ACADIA Pharma Limited • CerSci Therapeutics Incorporated • Amorsa Therapeutics Inc. • Acadia Pharmaceuticals Holdings Inc. • Levo Therapeutics, Inc. ...

IRS number

61376651

ACAD stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$24.83

Low target

$20.00

High target

$33.00

Latest filings (excl ownership)

View all

8-K

Submission of Matters to a Vote of Security Holders

8 May 23

Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview

1 May 23

Annual report to shareholders

27 Feb 23

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview

27 Feb 23

S-8

Registration of securities for employees

2 Nov 22

Transcripts

View all

ACAD

Earnings call transcript

2023 Q1

8 May 23

ACAD

Earnings call transcript

2022 Q4

27 Feb 23

ACAD

Earnings call transcript

2022 Q3

3 Nov 22

ACAD

Earnings call transcript

2022 Q2

9 Aug 22

ACAD

Earnings call transcript

2022 Q1

5 May 22

ACAD

Earnings call transcript

2021 Q4

1 Mar 22

ACAD

Earnings call transcript

2021 Q3

9 Nov 21

ACAD

Earnings call transcript

2021 Q2

5 Aug 21

ACAD

Earnings call transcript

2021 Q1

6 May 21

ACAD

Earnings call transcript

2020 Q4

25 Feb 21

Latest ownership filings

View all

ELIZABETH A. GAROFALO

BAKER BROS. ADVISORS LP

Financial summary

Financial statements Chart ACAD financial data

Quarter (USD)	Mar 23	Dec 22	Sep 22	Jun 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	296.67 mm	296.67 mm	296.67 mm	296.67 mm	296.67 mm	296.67 mm
Cash burn (monthly)	(no burn)	(no burn)	17.86 mm	13.68 mm	5.98 mm	4.64 mm
Cash used (since last report)	n/a	n/a	40.20 mm	30.79 mm	13.46 mm	10.44 mm
Cash remaining	n/a	n/a	256.46 mm	265.87 mm	283.21 mm	286.23 mm
Runway (months of cash)	n/a	n/a	14.4	19.4	47.4	61.7

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q1 2023

ACAD institutional ownership history Ownership history

94.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	226	227	-0.4%
Opened positions	37	33	+12.1%
Closed positions	38	26	+46.2%
Increased positions	72	71	+1.4%
Reduced positions	69	80	-13.8%

13F shares	Current	Prev Q	Change
Total value	2.86 tn	2.73 tn	+4.7%
Total shares	153.07 mm	155.45 mm	-1.5%
Total puts	199.20 k	146.80 k	+35.7%
Total calls	235.30 k	368.20 k	-36.1%
Total put/call ratio	0.8	0.4	+112.3%

Largest owners	Shares	Value	Change
Baker Bros. Advisors	41.94 mm	$789.28 bn	+0.0%
Vanguard	13.68 mm	$257.44 bn	+3.0%
BLK Blackrock	9.87 mm	$185.74 bn	-3.8%
RTW Investments	8.24 mm	$155.13 bn	+124.5%
FMR	7.85 mm	$147.67 bn	-15.9%
EcoR1 Capital	5.99 mm	$112.76 bn	0.0%
STT State Street	5.59 mm	$105.14 bn	-27.8%
D. E. Shaw & Co.	4.90 mm	$92.23 bn	+16.1%
T. Rowe Price	4.55 mm	$85.62 bn	+6.3%
MS Morgan Stanley	3.91 mm	$73.67 bn	+42.6%

Largest transactions	Shares	Bought/sold	Change
RTW Investments	8.24 mm	+4.57 mm	+124.5%
STT State Street	5.59 mm	-2.15 mm	-27.8%
Norges Bank	0.00	-1.95 mm	EXIT
Braidwell	0.00	-1.49 mm	EXIT
FMR	7.85 mm	-1.49 mm	-15.9%
Adage Capital Partners GP, L.L.C.	1.23 mm	+1.23 mm	NEW
Millennium Management	0.00	-1.20 mm	EXIT
MS Morgan Stanley	3.91 mm	+1.17 mm	+42.6%
MNGPF Man	0.00	-955.69 k	EXIT
Bain Capital Life Sciences Investors	0.00	-701.40 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ACAD insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
1 Jun 23	Baker Bros. Advisors	Common Stock	Grant	Acquire A	Yes	No	0	13,304	0.00	39,330,977
1 Jun 23	Baker Bros. Advisors	Common Stock	Grant	Acquire A	Yes	No	0	13,304	0.00	3,623,747
1 Jun 23	Baker Bros. Advisors	NQSO Common Stock	Grant	Dispose A	Yes	No	23.9	22,090	527.95 k	22,090
1 Jun 23	Adora Ndu	RSU Common Stock	Grant	Acquire A	No	No	0	6,652	0.00	6,652
1 Jun 23	Adora Ndu	Director Stock Options Common Stock	Grant	Acquire A	No	No	23.9	11,045	263.98 k	11,045
24 May 23	Baker Bros. Advisors	Common Stock	Buy	Acquire P	Yes	No	25.65	259,109	6.65 mm	39,317,673
24 May 23	Baker Bros. Advisors	Common Stock	Buy	Acquire P	Yes	No	25.65	24,113	618.50 k	3,610,443
24 May 23	Baker Bros. Advisors	Common Stock	Buy	Acquire P	Yes	No	25.5138	28,878	736.79 k	39,058,564
24 May 23	Baker Bros. Advisors	Common Stock	Buy	Acquire P	Yes	No	25.5138	2,688	68.58 k	3,586,330
24 May 23	Baker Bros. Advisors	Common Stock	Buy	Acquire P	Yes	No	25.2723	218,171	5.51 mm	39,029,686